Daiwa Securities Group
GLUE icon

Daiwa Securities Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Daiwa Securities Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-203
Closed -$3K – 1283
2025
Q4 		$3K Hold
203
– – ﹤0.01% 1274
2025
Q3 		$2K Hold
203
– – ﹤0.01% 1270
2025
Q2 		$1K Hold
203
– – ﹤0.01% 1262
2025
Q1 		$1K Hold
203
– – ﹤0.01% 1226
2024
Q4 		$1K Buy
+203
New +$1.52K ﹤0.01% 1252
2023
Q4 		– Sell
-136
Closed -$1K – 1347
2023
Q3 		$1K Hold
136
– – ﹤0.01% 1254
2023
Q2 		$1K Hold
136
– – ﹤0.01% 1275
2023
Q1 		$1K Hold
136
– – ﹤0.01% 1253
2022
Q4 		$1K Hold
136
– – ﹤0.01% 1270
2022
Q3 		$1K Hold
136
– – ﹤0.01% 1289
2022
Q2 		$1K Hold
136
– – ﹤0.01% 1290
2022
Q1 		$2K Hold
136
– – ﹤0.01% 1249
2021
Q4 		$3K Buy
+136
New +$2.85K ﹤0.01% 1240

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Daiwa Securities Group's GLUE Position: Q1 2026 in Review

Daiwa Securities Group sold out of Monte Rosa Therapeutics (GLUE) in Q1 2026, closing a stake of 203 shares — an estimated $3K sold.

Daiwa Securities Group first reported a position in GLUE in Q4 2021 and held it in 13 quarters. The position peaked at $3K in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Daiwa Securities Group reported no remaining Monte Rosa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 203 Monte Rosa Therapeutics shares in Q1 2026, an estimated $3K.
  • Daiwa Securities Group first reported a position in Monte Rosa Therapeutics in Q4 2021 and held it in 13 quarters.
  • Daiwa Securities Group's Monte Rosa Therapeutics position peaked at $3K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.